Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis

Blood

Volumn 113, Issue 14, 2009, Pages 3307-3313

  Ribrag, Vincent ^a   Koscielny, Serge ^b   Casasnovas, Olivier ^c   Cazeneuve, Cecile ^b   Brice, Pauline ^d   Morschhauser, Franck ^e   Gabarre, Jean ^f   Stamatoullas, Aspasia ^g   Lenoir, Gilbert ^b   Salles, Gilles ^h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b IGR   (France)

^c HÔPITAL DU BOCAGE   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g CENTRE HENRI BECQUEREL   (France)

^h UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL ISOLATION; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HODGKIN DISEASE; HOMOZYGOSITY; HUMAN; HUMAN CELL; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE REPEAT; ONCOGENE; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN LOCALIZATION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE; TREATMENT OUTCOME; WILD TYPE;

EID: 65349113148     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-148874     Document Type: Article

References (27)

1. Connors JM. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol. 2005;23: 6400-6408.
2. Ansell SM, Armitage JO. Management of Hodgkin lymphoma. Mayo Clin Proc. 2006;81:419-426.
3. Diehl V, Franklin J, Pfreundschuh M, et al. German Hodgkin's Lymphoma Study Group: standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386-2395.
4. Relling MV, DervieuxT. Pharmacogenetics and cancer therapy. Nat Rev Cancer. 2001;1:99-108.
5. Hohaus S, Massini G, D'Alo F, et al. Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis. Clin Cancer Res. 2003;9:3435-3440.
6. Evans WE, McLeod HL. Pharmacogenomics- drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538-549.
7. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348:529-537.
8. Marsh S, McLeod HL. Cancer pharmacogenetics. Br J Cancer. 2004;90:8-11.
9. Walgren RA, Meucci MA, McLeod HL. Pharma- cogenomic discovery approaches: will the real genes please stand up? J Clin Oncol. 2005;23:7342-7349.
10. Federico M, Bellei M, Brice P, et al. EBMT/GISL/ ANZLG/SFGM/GELA Intergroup HD01 Trial: high-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol. 2003; 21:2320-2325.
11. Fermé C, Eghbali H, Meerwaldt JH. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007;357:1916-1927.
12. Eghbali H, Brice P, Creemers G-Y, et al. Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): preliminary results of the EORTC-GELA H9-F Trial. Blood. 2005;106:814a.
13. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339:1506-1514.
14. Hohaus S, Di Ruscio A, Di Febo A, et al. Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin Cancer Res. 2005: 11:2175-2179.
15. Premawardhena A, Fisher CA, Liu YT, et al. The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol Dis. 2003;31:98-101.
16. Kaniwa N, Kurose K, Jinno H, et al. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleo- tide polymorphism 686C> T (P229L) found in an African-American. Drug Metab Dispos. 2005;33:458-465.
17. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA. 1998;95:13176-13181.
18. Garsa AA, McLeod HL, Marsh S. CYP3A4 and CYP3A5 genotyping by pyrosequencing. BMC Med Genet. 2005;6:19. 19. Watson MA, Stewart RK, Smith GB, et al. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis. 1998;19:275-280.
19. Ali-Osman F, Akande O, Antoun G, et al. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants: evidence for differential catalytic activity of the encoded proteins. J Biol Chem. 1997;272:10004- 10012.
20. Sweeney C, McClure GY, Fares MY, et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res. 2000;60:5621-5624.
21. Ambrosone CB, Sweeney C, Coles BF, et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res. 2001;61:7130-7135.
22. Millikan R, Pittman G, Tse CK, et al. Glutathione S-transferases M1, T1, and P1 and breast cancer. Cancer Epidemiol Biomarkers Prev. 2000;9:567-573.
23. Zhou S, Chin R, Kestell P, et al. Effects of anti- cancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. Br J Clin Pharmacol. 2001;52:129-136.
24. Andersen A, Holte H, Slordal L. Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients. Cancer Chemother Pharmacol. 1999;44:422-426.
25. Lear L, Nation RL, Stupans I. Effects of cyclophosphamide and adriamycin on rat hepatic microsomal glucuronidation and lipid peroxidation. Biochem Pharmacol. 1992;44:747-753.
26. Takikawa H, Yamazaki R, Sano N, et al. Biliary excretion of estradiol-17 beta-glucuronide in the rat. Hepatology. 1996;3:607-613.
27. Innocenti F, Iyer L, Ramirez J, Green MD, Ratain MJ. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos. 2001;29:686-692.